Affimed update
Updates on AFM13/AFM24 and outlook into 2023
Affimed gave a Q2 2022 business update that was mixed. Their second half is expected to have a few catalysts, but the company also announced a few delays which were disappointing. We think 2023 will have more material updates.
Recap of AFMD update:
AFM13 monotherapy topline data Q4
AFM13 as monotherapy in relapsed and refractory peripheral T-cell lymphom…